@societyofhemonc.bsky.social“Every year, SOHO gets better...more people, better presentations. It’s a significant improvement in the quality of interactions and interest from investigators, sponsors, and pharma.”
Dr. Guillermo Garcia-Manero @mdanderson.bsky.social on #SOHO2026 highlights
@societyofhemonc.bsky.socialThe latest myeloma news, all in one place. Find research updates, expert interviews, and more on SOHO Insider, including coverage from SOHO 2026. Go to sohoinsider.com/category/mul...
@societyofhemonc.bsky.social"It will be a better experience... easier logistics to get this drug to patients."
Dr. Saad Usmani @mskcancercenter.bsky.social on the practical advantages of iberdomide approval by the FDA. #SOHO2026
@societyofhemonc.bsky.social@societyofhemonc.bsky.socialDr. Jerald Radich highlights the most meaningful CML posters from #SOHO2026 click the link below to read more 👇️
@societyofhemonc.bsky.socialMegan Melody, MD, MS (@heMEGirl_MD) shares her thoughts on the important lymphoma abstracts presented at #SOHO2026. Read more: sohoinsider.com/meetings-con...
@onclive.bsky.socialWATCH 👀: Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, of @petermaccc.bsky.social, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.
Full video ➡️: www.onclive.com/view/dr-ande...
#leusm #oncology #SOHO2026 @societyofhemonc.bsky.social
@societyofhemonc.bsky.socialAt #SOHO2026, Dr. Naveen Pemmaraju of @mdanderson.bsky.social shared data for DISC-3405 in polycythemia vera.
@hematologyadvisor.bsky.socialA phase 2 study presented at #SOHO2026 evaluated frontline low-dose nivolumab (40 mg) + AVD for #HodgkinLymphoma:
🔹 95.8% ORR after 2 cycles
🔹 86.7% ORR after 6 cycles
🔹 75% total drug cost reduction vs standard dose
🩸Read more: https://bit.ly/4yjkaZC
@cancertherapyadv.bsky.socialNew research presented at #SOHO2026 highlighted key advances in #AML, including the timing of treatment initiation in newly diagnosed AML and as well as the treatment strategies in older or unfit patients.
🔗 Read our feature on all the research here: https://bit.ly/4rxcErO
@societyofhemonc.bsky.social
@societyofhemonc.bsky.socialThank you to all our attendees and SOHO members who made #SOHO2026 a success! 🎉 More than 3,100 attendees joined us this year our biggest meeting yet.
@onclive.bsky.social“We can tailor treatment and make nuanced decisions for the individual patient in front of us,” Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, of @petermaccc.bsky.social said of CLL management. @societyofhemonc.bsky.social #SOHO2026 #lymsm #hematology
Full interview: www.onclive.com/view/cll-tre...
@societyofhemonc.bsky.socialTelomere biology disorders linked to substantial morbidity and frequent clonal hematopoiesis
Data presented at #SOHO2026 by Dr. Olisaemeka Ogbue of @MayoClinic. #HemeOnc #BloodCancer
@onclive.bsky.socialBexobrutideg drove responses across treatment lines in CLL/SLL, including in a subgroup of patients with treatment-naive disease. Dive into the #SOHO2026 data here #leusm #oncology www.onclive.com/view/bexobru...
@onclive.bsky.social📈Updated data from the phase 3 ECHO trial showed improved efficacy for acalabrutinib plus BR in frontline MCL, providing insight about treatment sequencing.
Full details ➡️: www.onclive.com/view/echo-sh...
@societyofhemonc.bsky.socialMissed any #SOHO2026 sessions? Catch them on demand with the SOHO365 mobile app. Don't just take our word for it, hear from Dr. Fadi Haddad 🎥
Download the app here. sohoonline.org/SOHO/SOHO/Mo...
@onclive.bsky.social📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.
Read more here ➡️: www.onclive.com/view/pirtobr...
@onclive.bsky.social🤔 Lower risks of TLS were shown for venetoclax-based regimens in patients with CLL compared with MCL, according to a real-world analysis.
Full details 📰: onclive.com/view/venetoc...
#leusm #lymsm #oncology #SOHO2026
@societyofhemonc.bsky.social
@hematologyadvisor.bsky.socialThe phase 3 TERZO trial presented at #SOHO2026 investigating whether duvelisib monotherapy can improve progression-free survival over standard chemotherapy in adults with relapsed or refractory nodal T cell-follicular helper lymphoma.
See more: https://bit.ly/4yEVquZ
